The Company's novel pharmaceutical product candidates are designed to improve the delivery of cancer drugs for more effective treatment of solid tumors. Two product candidates of the Company have been, or are being, evaluated in human clinical trials. Injectable Gel and MPI 5020 Radiopotentiator. The Company also in-licenses product candidates for development. The Company currently owns worldwide marketing rights for all its products under development, except for tezacitabine in Japan.
Revenues reflect an increased customer base.
All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Data and information is provided for informational purposes only, and is not intended for trading purposes.